Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.
[More]
A study presented today at the International Liver CongressTM 2013 - which evaluated the relationship between non-alcoholic fatty liver disease (NAFLD), early predictors of atherosclerosis and the 10-year Framingham risk score (FRS) - showed that NAFLD increases the risk of early atherosclerotic lesions independent of established cardiovascular (CV) risk factors.
[More]
Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a phase 1 clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor.
[More]
The American Association of Clinical Endocrinologists today announced the publication of its comprehensive diabetes management algorithm created to guide primary care physicians, endocrinologists and other health care professionals in the treatment of prediabetes and type 2 diabetes mellitus patients.
[More]
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
[More]
New Orleans residents continue to face a three-fold increased risk of heart attack post-Katrina-a trend that has remained unchanged since the storm hit in 2005, according to research being presented at the American College of Cardiology's 62nd Annual Scientific Session.
[More]
Well it hasn’t varied at all over the last 15 years, which I find pretty amazing because we’ve been through a lot of changes in general practice. Yet, the average length of consultation, as measured from a start to finish time, in a sample of 40,000 consultations in Australia in a year, shows that the average is 15 minutes and the median is 13 minutes.
[More]
Bariatric surgery for obese patients is not cost-saving relative to medical care, shows a 6-year follow-up study in JAMA Surgery.
[More]
Taiwanese individuals with bipolar disorder are at an increased risk for hypertension when compared with the general population, research shows.
[More]
Atrial fibrillation may play an intermediary role in the relationship between obstructive sleep apnea and stroke, research findings suggest.
[More]
Novartis announced today that the US Food and Drug Administration (FDA) has approved Zortress (everolimus) for the prophylaxis of organ rejection in adult patients receiving a liver transplant.
[More]
Researchers have identified a microRNA liver gene, miR-27b, which regulates lipid (cholesterol or fat) levels in the blood. This regulator gene controls multiple genes involved in dyslipidemia-abnormal blood cholesterol levels that can contribute to heart disease.
[More]
Researchers have identified a microRNA liver gene, miR-27b, which regulates lipid (cholesterol or fat) levels in the blood. This regulator gene controls multiple genes involved in dyslipidemia—abnormal blood cholesterol levels that can contribute to heart disease.
[More]
Patients who feel confident and engaged in decisions about their health and taking care of themselves incur lower healthcare costs as a result of their improved outcomes, suggests a study in Health Affairs.
[More]
Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.
[More]
Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the pivotal Phase 3 METIV-HCC (MET-high patients with tivantinib in HCC) trial of tivantinib (ARQ 197).
[More]
Women who have hypertensive complications during pregnancy are at increased risk for developing chronic kidney disease and end-stage renal disease, shows a study in the Canadian Medical Association Journal.
[More]
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for KYNAMROTM (mipomersen sodium) injection.
[More]
Women who have hypertensive complications during pregnancy are at increased risk for developing chronic kidney disease and end-stage renal disease, shows a study in the Canadian Medical Association Journal.
[More]
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces completion of patient enrollment in the phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
[More]